Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): Assessment of severity in patients with sepsis

Hélène Chung, Angelo Corti, Luca Crippa, Francis Schneider, Marie Hélène Metz-Boutigue, Patrick Garnero

Research output: Contribution to journalArticle

Abstract

Context: Proteolytic fragments of chromogranin A (CgA) including the CgA 1-76 fragment (called vasostatin-I [VS-I]) could be a useful biomarker of sepsis, but there is no available immunoassay. Methods: A sandwich ELISA for VS-I was developed, and plasma VS-I was measured in 30 healthy controls and 60 critically ill patients with sepsis. Results: The ELISA showed intra- and inter-Assay coefficients of variations (CVs) below 4 and 9%. Plasma VS-I was significantly increased compared with controls in patients with sepsis, severe sepsis, and sepsis shock (p <0.0001). Receiver operating curve (ROC) analyses indicated that plasma VS-I was more sensitive and specific than plasma CgA to diagnose sepsis and to assess its severity. Conclusions: The measurements of plasma VS-I with this new ELISA may be useful for the clinical investigation of patients with sepsis.

Original languageEnglish
Pages (from-to)430-434
Number of pages5
JournalBiomarkers
Volume17
Issue number5
DOIs
Publication statusPublished - Aug 2012

Keywords

  • Biomarker
  • Chromogranin A
  • Sepsis
  • Vasostatin

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): Assessment of severity in patients with sepsis'. Together they form a unique fingerprint.

  • Cite this